Published research on Albendazole
5 peer-reviewed publications on Albendazole in oncology research, clinical work first, then laboratory studies. Each entry reports what the authors stated; follow the link for the full paper.
- Clinical trial
In 36 patients with refractory solid tumours, a maximum tolerated dose of oral albendazole was defined with myelosuppression as the dose-limiting toxicity, and 4 of 24 assessable patients had a tumour marker fall of at least 50%.
- Clinical trial
In seven patients with refractory colorectal cancer or hepatocellular carcinoma, albendazole decreased CEA in two patients and stabilised tumour markers in three, while three further patients were withdrawn for severe neutropenia that probably contributed to one death.
- In vivo
In nude mice bearing OVCAR-3 peritoneal tumours, intraperitoneal albendazole markedly suppressed ascites formation and reduced tumour vascularity, which the authors attributed to reduced tumour VEGF production.
- In vivo
In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole
Albendazole inhibited proliferation of human, rat and mouse hepatocellular carcinoma cell lines by more than 80% at micromolar concentration and profoundly suppressed growth of SKHEP-1 tumours in nude mice.
- In vitro
Albendazole sensitizes cancer cells to ionizing radiation
Albendazole induced DNA damage and G2/M arrest in metastatic melanoma and small cell lung cancer cell lines at clinically achievable concentrations and synergistically increased their sensitivity to radiation.
Albendazole in the catalog (specifications, pack sizes, Certificate of Analysis)